

dolinnov

Developing Precision Pump Modulators (PPMs)
a novel class of non-opioid medicines



Dolinnov is the world's first biotech company dedicated to targeting FXYP2, a regulator of neuronal excitability in the DRG

Our Innovation



New innovative target: FXYP2 – Peripheral nervous system.



Delivery Innovation : Lipid Antisense Oligonucleotide (L-ASO) therapy designed to precisely silence mRNA sequences of FXYP2.



Indications : Severe chronic pain.



Translational design: Homologous human/animal sequences for seamless preclinical → clinical development.

Value proposition

- > **Chronic pain affects 20% of the population** in developed countries, creating a massive need for the first truly effective non-opioid therapy.
- > Traditional approaches blocking ion channels (Nav1.7, Nav1.8, etc.) have repeatedly failed due to **limited efficacy and intolerable side effects**.
- > **Dolinnov introduces a new paradigm:** instead of blocking ion channels, we precisely modulate Na⁺/K⁺-ATPase regulatory system in DRG neurons by selectively silencing FXYP2, the key modulator of neuronal excitability
- > This mechanism enables a **breakthrough solution for severe chronic pain**, which remains inadequately treated in over 50% of patients.
- > **Optimized safety profile with peripherally acting therapy** that eliminates CNS exposure, avoiding side effects.

Series A financing

- > **\$22M**
- > End preclinical studies
- > Scale-up CMC
- > Conduct Phase I/IIa

Strategy & Market Opportunity

Achieve a robust POC and regulatory readiness to enable expansion into multiple high-value indications

> Key Markets

- > **+\$10B** severe neuropathic pain opportunity
- > ASO market growth: **\$6.1B → \$24B (2033)**
- > **>50M** patients lack effective treatment options

Main publications

JCI insight PLoS scientific reports

Partners



A Breakthrough for Chronic Pain

 FXRD - innovative target	> Hyperexcitability regulator: protein - gamma subunit of the Na⁺/K⁺-ATPase > PNS target: No side effects on CNS
 ASO Precision therapeutic modality	> First in class L-ASO for Chronic pain > Proprietary chemistry conjugate
 A Broad spectrum of indications	> Breakthrough preclinical data demonstrate strong efficacy in : • Neuropathic Pain • Inflammatory Pain

4 PATENTS UNDER EXCLUSIVE LICENSE

N°1
TECHNO

N°2
TARGET

N°3
PRODUCT

N°4
IV ROA

Founders



Grégoire Serra
CEO



Dr. Jean Philippe Annereau
CSO



Dr. Stéphanie Venteo
Principal Scientific

SAB



Dr. Jordi Serra
Expert in microneurography



Clifford Woolf
World Leader in Pain Neurobiology



Dr. Ben Johnston
Clinical Expert in Pain & Neuromodulation



Pr. Nadine Attal
International Expert in Pain



Leen Thielemans
Chief Development Officer



Pr. Céline Greco
Expert in Rare Pain Disorders

Dolinnov Global development plan

